Moore Capital Management LP Raises Holdings in Ascendis Pharma A/S $ASND

Moore Capital Management LP boosted its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 38.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 125,000 shares of the biotechnology company’s stock after acquiring an additional 35,000 shares during the period. Moore Capital Management LP’s holdings in Ascendis Pharma A/S were worth $26,655,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. Avoro Capital Advisors LLC increased its holdings in shares of Ascendis Pharma A/S by 2.6% in the 3rd quarter. Avoro Capital Advisors LLC now owns 5,110,000 shares of the biotechnology company’s stock valued at $1,015,919,000 after acquiring an additional 130,000 shares during the last quarter. Capital International Investors raised its position in shares of Ascendis Pharma A/S by 0.4% during the 3rd quarter. Capital International Investors now owns 3,060,616 shares of the biotechnology company’s stock worth $608,481,000 after acquiring an additional 13,685 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Ascendis Pharma A/S by 95.9% during the 3rd quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company’s stock worth $357,645,000 after acquiring an additional 880,836 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of Ascendis Pharma A/S by 29.3% during the 4th quarter. Principal Financial Group Inc. now owns 1,026,407 shares of the biotechnology company’s stock worth $218,871,000 after acquiring an additional 232,730 shares in the last quarter. Finally, Perceptive Advisors LLC acquired a new stake in shares of Ascendis Pharma A/S during the 2nd quarter worth about $166,367,000.

Ascendis Pharma A/S Trading Down 0.0%

Shares of ASND stock opened at $231.15 on Thursday. The business’s 50 day moving average is $232.16 and its two-hundred day moving average is $224.09. Ascendis Pharma A/S has a twelve month low of $160.86 and a twelve month high of $250.74. The company has a market capitalization of $14.42 billion, a P/E ratio of 26.66 and a beta of 0.39. The company has a current ratio of 1.00, a quick ratio of 0.72 and a debt-to-equity ratio of 0.79.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.11. The company had revenue of $285.45 million during the quarter, compared to analysts’ expectations of $362.47 million. Equities analysts forecast that Ascendis Pharma A/S will post 14.25 EPS for the current year.

Wall Street Analysts Forecast Growth

ASND has been the topic of several research analyst reports. Barclays raised their target price on Ascendis Pharma A/S from $342.00 to $345.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Stifel Nicolaus set a $332.00 target price on Ascendis Pharma A/S in a research report on Wednesday, March 4th. The Goldman Sachs Group restated a “buy” rating and set a $255.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. Wall Street Zen upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Bank of America raised their price target on Ascendis Pharma A/S from $262.00 to $292.00 and gave the stock a “buy” rating in a research note on Thursday, April 16th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of “Buy” and an average target price of $295.39.

Insider Activity at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime purchased 400 shares of Ascendis Pharma A/S stock in a transaction dated Tuesday, May 26th. The stock was acquired at an average cost of $237.80 per share, with a total value of $95,120.00. Following the acquisition, the director directly owned 400 shares of the company’s stock, valued at $95,120. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Flemming Steen Jensen sold 19,460 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $238.49, for a total value of $4,641,015.40. Additional details regarding this sale are available in the official SEC disclosure. 40.00% of the stock is owned by company insiders.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.